WAVE Life Sciences (NASDAQ:WVE) Issues Quarterly Earnings Results

WAVE Life Sciences (NASDAQ:WVE) announced its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03), FiscalAI reports. The company had revenue of $2.27 million during the quarter, compared to analysts’ expectations of $7.45 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%.

Here are the key takeaways from WAVE Life Sciences’ conference call:

• WVE-007 obesity development advanced into Phase IIa with dosing underway in patients with higher BMI and comorbidities. The company is also planning combination-with-incretin and post-incretin maintenance studies this year, targeting fat loss with muscle preservation and potentially once- or twice-yearly dosing.
• WVE-006 produced data the company says support treatment of both lung and liver manifestations of AATD with infrequent subcutaneous dosing. The FDA granted a meeting expected later this summer to discuss a potential accelerated-approval pathway, while data from the 600 mg cohort are expected in the second half of 2026.
• Wave remains on track to submit a CTA for WVE-008 in PNPLA3 liver disease in 2026. The RNA-editing program aims to restore functional protein rather than silence the target, with preclinical data showing more than 50% editing and reduced lipid accumulation versus siRNA.
• The company is exploring partnerships for its DMD candidate WVE-N531 before filing an NDA, citing an evolving regulatory and commercial landscape. Management said it continues to believe in the program but will reassess filing plans based on regulatory developments and partnership progress.
• Second-quarter revenue fell to $2.3 million from $8.7 million a year earlier, while the net loss widened to $69.4 million from $50.5 million as R&D and G&A spending increased. Wave ended the quarter with $490.6 million in cash and expects funding into Q3 2028, excluding potential future GSK milestone payments.

WAVE Life Sciences Trading Down 0.9%

Shares of WAVE Life Sciences stock traded down $0.05 during trading on Thursday, reaching $5.76. The company’s stock had a trading volume of 3,032,883 shares, compared to its average volume of 2,240,663. The company has a 50-day moving average price of $5.99 and a two-hundred day moving average price of $9.00. The firm has a market cap of $1.11 billion, a PE ratio of -5.43 and a beta of -1.29. WAVE Life Sciences has a fifty-two week low of $5.02 and a fifty-two week high of $21.73.

Analyst Ratings Changes

Several equities research analysts recently commented on WVE shares. Citigroup cut their price target on shares of WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, May 4th. HC Wainwright reaffirmed a “buy” rating on shares of WAVE Life Sciences in a report on Thursday, June 11th. Zacks Research upgraded WAVE Life Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Truist Financial began coverage on WAVE Life Sciences in a report on Wednesday, April 29th. They issued a “buy” rating and a $15.00 target price for the company. Finally, Wall Street Zen raised WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, WAVE Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.41.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of WVE. Smartleaf Asset Management LLC raised its holdings in shares of WAVE Life Sciences by 645.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after buying an additional 1,942 shares during the last quarter. Russell Investments Group Ltd. increased its position in WAVE Life Sciences by 1,441.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock valued at $73,000 after acquiring an additional 9,284 shares during the period. Tower Research Capital LLC TRC raised its stake in WAVE Life Sciences by 44.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock valued at $76,000 after acquiring an additional 3,609 shares during the last quarter. Prudential Financial Inc. acquired a new stake in WAVE Life Sciences during the 2nd quarter worth approximately $80,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in WAVE Life Sciences during the 3rd quarter worth approximately $87,000. 89.73% of the stock is currently owned by institutional investors and hedge funds.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.